Institution
Sichuan Cancer Hospital
Also known as: Second People's Hospital of Sichuan Province · Sichuan Provincial Tumor Hospital · 四川省肿瘤研究所
- 136running trials
- 25closed trials
- 6,524publications (OpenAlex)
Running trials
Recruiting
Not yet recruiting
Not yet recruiting
Recruiting
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
Recruiting
Not yet recruiting
A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
Not yet recruiting
Recruiting
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Not yet recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Enrolling by invitation
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
Recruiting
Recruiting
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Showing 50 of 136.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer48 recruiting
- Colorectal cancer10 recruiting
- Metastatic breast cancer7 recruiting
- Head and neck cancer5 recruiting
- Gastric and oesophageal cancer4 recruiting
- Liver and biliary tract cancer4 recruiting
- Triple-negative breast cancer3 recruiting
- Bladder cancer2 recruiting
- Diffuse large B-cell lymphoma2 recruiting
- Pancreatic cancer2 recruiting
- Prostate cancer2 recruiting
- Sarcoma2 recruiting
- Cervical cancer1 recruiting
- Childhood cancers1 recruiting
- Endometrial cancer1 recruiting
- Mantle cell lymphoma1 recruiting
- Mesothelioma1 recruiting
- Multiple myeloma1 recruiting
- Neuroendocrine tumours1 recruiting
- Ovarian cancer1 recruiting
- Thyroid cancer1 recruiting
Closed trials
Terminated
Recruiting
Completed
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Completed
Recruiting
Terminated
Completed
Completed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Completed
Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
Completed
Completed
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Completed
Completed
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Completed
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
Completed
Completed
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
Completed
Registry name variants (32)
Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.
Sichuan Cancer Hospital
Chengdu, Sichuan 610213
129 trials
Sichuan Cancer Hospital
Shanghai, Sichuan
2 trials
Contact: Astellas Pharma Global Development, Inc.
NCT05579366Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Sichuan Cancer Hospital
Chendu
1 trial
Sichuan Cancer Hospital
Cheng Du Shi, 610044
1 trial
Sichuan Cancer Hospital
Sichuan, 610041
1 trial
Sichuan Cancer Hospital - 3227
Chengdu, Sichuan 610041
1 trial
Sichuan Cancer Hospital
Chengdu, Sichuan 610041
1 trial
Sichuan Cancer Hospital/Medical Oncology Department
Chengdu, Sichuan 00000
1 trial
Contact: Wenxiu Yao, Site 6728
Sichuan Cancer Hospital. (Site 0050)
Chengdu, Sichuan 610041
1 trial
Sichuan Cancer hospital. (Site 0128)
Chengdu, Sichuan 610213
1 trial
Sichuan Cancer Hospital (Site 0527)
Chengdu, Sichuan 610041
1 trial
Sichuan Cancer hospital. (Site 0831)
Chengdu, Sichuan 610213
1 trial
Contact: Study Coordinator
Sichuan Cancer Hospital (Site 1018)
Chengdu, Sichuan 610041
1 trial
Sichuan Cancer hospital. (Site 1327)
Chengdu, Sichuan 610042
1 trial
Sichuan Cancer hospital. (Site 1609)
Chengdu, Sichuan 610213
1 trial
Contact: Study Coordinator
Sichuan Cancer hospital (Site 2101)
Chengdu, Sichuan 610041
1 trial
Contact: Study Coordinator
Sichuan Cancer hospital. (Site 2218)
Chengdu, Sichuan 610213
1 trial
Contact: Study Coordinator
Sichuan Cancer hospital. (Site 2421)
Chengdu, Sichuan 610042
1 trial
Sichuan Cancer Hospital. (Site 2739)
Chengdu, Sichuan 610213
1 trial
Contact: Study Coordinator
Sichuan Cancer hospital. (Site 2822)
Chengdu, Sichuan 610042
1 trial
Sichuan Cancer hospital. (Site 2923)
Chengdu, Sichuan 610042
1 trial
Sichuan Cancer hospital. (Site 3030)
Chengdu, Sichuan 610213
1 trial
Sichuan Cancer hospital. (Site 3105)
Chengdu, Sichuan 610042
1 trial
Sichuan Cancer hospital. (Site 3109)
Chengdu, Sichuan 610042
1 trial
Sichuan Cancer Hospital. (Site 3110)
Chengdu, Sichuan 610041
1 trial
NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Contact: Study Coordinator
Sichuan Cancer Hospital. (Site 3111)
Chengdu, Sichuan 610041
1 trial
Contact: Study Coordinator
Sichuan Cancer hospital. (Site 3127)
Chengdu, Sichuan 610042
1 trial
Sichuan Cancer Hospital. (Site 4039)
Chengdu, Sichuan 610041
1 trial
Sichuan Cancer Hospital. (Site 5006)
Chengdu, Sichuan 610213
1 trial
Sichuan Cancer Hospital. (Site 5018)
Chengdu, Sichuan 610041
1 trial
Sichuan Cancer Hospital, University of Electronic Science and Technology of China
Chengdu, Sichuan 610000
1 trial
Sichuan Provincial Tumor Hospital
Chengdu, Sichuan 610000
1 trial
NCT06532591Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
Contact: Li Juan, MD.
Conditions
Diseases this institution publishes on or runs trials for.
- Lung cancer159 works · 79 trials
- Gastric and oesophageal cancer75 works · 20 trials
- Cervical cancer26 works · 6 trials
- Brain metastases16 works · 0 trials
- Thyroid cancer13 works · 2 trials
- Head and neck cancer11 works · 9 trials
Institution data: ROR 029wq9x81 (CC0-1.0)Updated 15 Nov 2026